Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

llion.

"While, clearly the early part of 2009 produced disappointing clinical results for maribavir, 2008 was a very successful year for ViroPharma -- from strong financial results to great execution in all aspects of our business to the transformational acquisition of Lev Pharmaceuticals and the launch of Cinryze. As a result we believe we have positioned ourselves with a number of growth drivers and multiple opportunities for success," stated Vincent Milano, ViroPharma's president and chief executive officer. "Those who follow our company can look for a number of exciting milestones throughout the upcoming year, such as progress on Cinryze, including the ongoing commercial launch and our acute indication sBLA with a June PDUFA date; continued success with Vancocin; the planned initiation of clinical studies for NTCD; and continued strong financial performance."

Net sales of Vancocin were $50.0 million for the fourth quarter of 2008 and $232.3 million for the year ended December 31, 2008, as compared to $47.7 million and $203.8 million in the respective 2007 periods.

Operating income for the year ended December 31, 2008 was $78.7 million. Our operating loss for the fourth quarter 2008 was $3.4 million. These amounts are compared to operating income of $115.8 million and $19.0 million for the year and fourth quarter of 2007, respectively. Operating income decreased in both comparative periods primarily due to increased amortization expense, the growth in the investment in our pipeline and increased SG&A costs.

Net loss in the fourth quarter ended December 31, 2008 was $1.0 million, compared to net income of $20.4 million for the same period in 2007. For the twelve months ended December 31, 2008, net income was $67.6 million, compared to $95.4 million for the same period in 2007. Net loss per share for the quarter ended December 31, 2008 was $0.01 per share, basic and
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2DTS Improves Efficiency for Life Science Document Translations 2
... India, April 21 /PRNewswire-Asia/ --,QIAGEN and the Chittaranjan ... establish the first large-scale cervical cancer screening,program for ... QGEN ; Frankfurt Prime,Standard: QIA) will provide ... the primary cause of cervical cancer. CNCI will ...
... Hoping that science will cast a spell on local ... team is starting a program that will harness the ... technical subjects resonate in local classrooms. , Funded by ... Foundation, the Innovations in Nanotechnology and NanoSciences initiative will ...
... Thoratec Corporation (Nasdaq: THOR ), a world ... support and restore failing hearts, said today that it ... FDA seeking to add the intended use of Destination ... ventricular assist system). The HeartMate II is a next ...
Cached Biology Technology:QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 2QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 3QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 4QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata 5UH initiative will use 'Harry Potter' to conjure love for science in Houston-area schools 2UH initiative will use 'Harry Potter' to conjure love for science in Houston-area schools 3Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R) 2Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R) 3Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R) 4
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
(Date:4/17/2014)... and plant life, but there,s an invisible machine underground. ... soil, decomposing organic matter and releasing carbon into the ... in ecological systems, their identities have only now been ... genetic map of more than 10,000 species of fungi ... in the Proceedings of the National Academy of ...
(Date:4/17/2014)... of Domestication," a special feature of The ... ( PNAS ) published April 29, raises a number ... history that most of us take for granted. At ... many spots around the globe shifted from hunting animals ... plants. , It seems so straightforward and yet the ...
Breaking Biology News(10 mins):New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4
... shrimp-like creature at the heart of the Antarctic food ... Southern Ocean with iron stimulating the growth of ... capacity for natural storage of carbon dioxide. ... Oceanography , an international team of researchers describe how ...
... viable future biofuel especially if harvested in summer. ... could provide an important alternative to terrestrial grown biofuels; ... a seasonal basis. Harvesting the kelp in July when ... sugar release for biofuel production. , "The storage carbohydrate ...
... by women of advanced maternal age (over 35 years) ... of meiosis a critical process of chromosome duplication ... of oocytes and sperm and leading to abnormalities ... failure, pregnancy loss or, more rarely, the birth of ...
Cached Biology News:Antarctic krill help to fertilize Southern Ocean with iron 2Biofuels from the sea 2Could ovarian stimulation cause an increase in oocyte chromosome abnormalities? 2Could ovarian stimulation cause an increase in oocyte chromosome abnormalities? 3
... monoclonal antibody raised against a partial recombinant IFNA2. ... a.a.) partial recombinant protein is produced in E. ... 8 IU/ mg. OMIM: ... Lot Number: MM951100564 MA ...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Biology Products: